GLP-1

News

Black and white image of a white flag of surrender

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1

Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.

News

Hims & Hers copies Novo Nordisk's new Wegovy pill

Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version.

News

Novo Nordisk slumps on tougher 2026 financial outlook

Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.

News

Lilly names Pennsylvania site for its latest US facility

Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US - a $3.5bn facility in Pennsylvania.

News

Man with measuring tape around his torso

GLP-1 drugs linked to pancreatitis, gallbladder problems

Users of weight-loss therapies based on GLP-1 agonists have been warned to be aware of a rare complication, pancreatitis, that can be severe.

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1

Hims & Hers copies Novo Nordisk's new Wegovy pill

Novo Nordisk slumps on tougher 2026 financial outlook

Lilly names Pennsylvania site for its latest US facility

GLP-1 drugs linked to pancreatitis, gallbladder problems

Roche claims midstage win for obesity injectable

Pfizer takes 25-valent Prevnar follow-up into phase 3

Discover a new era of healthcare panel engagement: Grounded ...

GLP-1

Editor's Picks